Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines by Ha, Kevin CH et al.
RESEARCH ARTICLE Open Access
Identification of gene fusion transcripts by
transcriptome sequencing in BRCA1-mutated
breast cancers and cell lines
Kevin CH Ha
1,2, Emilie Lalonde
1,2, Lili Li
1,3,4, Luca Cavallone
3,4, Rachael Natrajan
5, Maryou B Lambros
5,
Costas Mitsopoulos
5, Jarle Hakas
5, Iwanka Kozarewa
5, Kerry Fenwick
5, Chris J Lord
5, Alan Ashworth
5,
Anne Vincent-Salomon
6, Mark Basik
4,7,8, Jorge S Reis-Filho
5, Jacek Majewski
1,2 and William D Foulkes
1,3,4,7*
Abstract
Background: Gene fusions arising from chromosomal translocations have been implicated in cancer. However, the
role of gene fusions in BRCA1-related breast cancers is not well understood. Mutations in BRCA1 are associated with
an increased risk for breast cancer (up to 80% lifetime risk) and ovarian cancer (up to 50%). We sought to identify
putative gene fusions in the transcriptomes of these cancers using high-throughput RNA sequencing (RNA-Seq).
Methods: We used Illumina sequencing technology to sequence the transcriptomes of five BRCA1-mutated breast
cancer cell lines, three BRCA1-mutated primary tumors, two secretory breast cancer primary tumors and one non-
tumorigenic breast epithelial cell line. Using a bioinformatics approach, our initial attempt at discovering putative gene
fusions relied on analyzing single-end reads and identifying reads that aligned across exons of two different genes.
Subsequently, latter samples were sequenced with paired-end reads and at longer cycles (producing longer reads). We
then refined our approach by identifying misaligned paired reads, which may flank a putative gene fusion junction.
Results: As a proof of concept, we were able to identify two previously characterized gene fusions in our samples
using both single-end and paired-end approaches. In addition, we identified three novel in-frame fusions, but none
were recurrent. Two of the candidates, WWC1-ADRBK2 in HCC3153 cell line and ADNP-C20orf132 in a primary
tumor, were confirmed by Sanger sequencing and RT-PCR. RNA-Seq expression profiling of these two fusions
showed a distinct overexpression of the 3’ partner genes, suggesting that its expression may be under the control
of the 5’ partner gene’s regulatory elements.
Conclusions: In this study, we used both single-end and paired-end sequencing strategies to discover gene
fusions in breast cancer transcriptomes with BRCA1 mutations. We found that the use of paired-end reads is an
effective tool for transcriptome profiling of gene fusions. Our findings suggest that while gene fusions are present
in some BRCA1-mutated breast cancers, they are infrequent and not recurrent. However, private fusions may still be
valuable as potential patient-specific biomarkers for diagnosis and treatment.
Background
Gene fusions are the result of aberrant chromosomal
translocations that joins together the exons of two unre-
lated genes, producing a chimeric mRNA transcript and
protein. Many gene fusions that contribute to oncogen-
esis have been described in literature [1], such as the
well-documented BCR-ABL in chronic myelogenous leu-
kemia [2]. Recently, there has been greater interest in
utilizing massively parallel RNA sequencing (RNA-Seq)
data to identify gene fusions [3-5]. RNA-Seq has
emerged as a powerful tool to profile the entire tran-
scriptome at a level of detail unattainable by microarrays
[ 6 , 7 ] .H e r e ,w es o u g h tt oi d e n t i f yp u t a t i v eg e n ef u s i o n
mRNA transcripts in BRCA1-mutated breast cancers.
Mutations in BRCA1 (and BRCA2)c o n f e rah i g hr i s k
for breast cancer, with a lifetime risk of up to 80% [8,9].
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ovarian cancer [10]. Breast cancer is a highly heteroge-
neous malignancy, as demonstrated by gene expression
microarray studies that proposed various molecular sub-
types [11,12]. BRCA1-related breast cancers have been
described to share similarities with basal epithelial
(basal-like) and triple-negative phenotypes [13,14].
Basal-like breast cancers have an expression profile that
is similar to that found in normal basally-positioned
breast epithelial cells [11], and the majority of these are
triple-negative. In other words, they do not express the
genes estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2
(HER2/neu) [15]. Furthermore, when studied by immu-
nohistochemistry, basal-like tumors are found to express
one or more of cytokeratins 5, 14, and 17, c-KIT and
epidermal growth factor receptor (EGFR) [16,17].
Recurrent gene fusions have been implicated in some
forms of breast cancer, such as ETV6-NTRK3 in secre-
tory breast ductal carcinoma [18]. The role of gene
fusions in BRCA1 breast cancers, however, has not been
well explored. One motivation to study them in these
cancers is that BRCA1 is involved in many cellular pro-
cesses as well as in repairing double-stranded DNA
breaks (DSBs) mediated by homologous recombination
(HR) [19]. HR is error-free and involves repairing DSBs
by merging two broken ends based on sequence homol-
ogy [20]. When BRCA1 is deficient in HR, evidence sup-
porting increased activity of a second repair pathway,
non-homologous end joining (NHEJ), has been shown
[ 2 1 ] .W h i l et h er o l eo fB R C A 1i nN H E Ji sn o tw e l l
known, NHEJ is more vulnerable to errors as it involves
repairing DSBs by incorporating or deleting nucleotides
a tt h es i t eo fb r e a k a g et om a k et h et w ob r o k e ne n d s
compatible for ligation [22]. Errors resulting from NHEJ
can lead to increased chromosomal aberrations, translo-
cations, and unchecked DNA damage [23]. Furthermore,
Stephens et al. [24] investigated genomic rearrange-
ments in 24 breast cancer genomes with and without
BRCA1 mutations and found genomic rearrangements
to be significantly widespread. Hence, we hypothesized
that deficiencies in BRCA1 would cause increased chro-
mosomal instability in a tumor cell due to impaired
DNA repair pathways and NHEJ dysfunction. The
resulting chromosomal lesions may potentially lead to
the creation of gene fusions that can be detected in the
transcriptome.
We demonstrate the use of RNA-Seq to investigate
the transcriptomes of BRCA1-mutated breast cancers
for gene fusions. RNA-Seq is capable of producing sin-
gle-end (SE) reads (i.e. reads sequenced from only one
end of the cDNA fragment) or paired-end (PE) reads (i.
e. both ends of the fragment are sequenced). We utilized
both strategies for the discovery of gene fusions. Our
analysis illustrates the feasibility of applying RNA-Seq to
characterize gene fusions at the transcriptome level.
Methods
Sample collection and RNA-Seq preparation
We studied the transcriptomes of five BRCA1-mutated
breast cancer cell lines (one of which is a matched lym-
phocyte cell line), three BRCA1-mutated primary
tumors, two secretory breast ductal carcinoma primary
tumors (SEC1 and SEC2) and one non-tumorigenic
breast epithelial cell line (Table 1). To experimentally
validate and detect for recurrence of our candidate gene
fusions, we additionally obtained a cDNA panel of 57
breast cancers (19 BRCA1-mutated, 17 BRCA2-mutated,
and 21 BRCA1/2-wild-type). Institutional Review Board-
approved written informed consent forms were com-
pleted by all individuals whose tumor samples were
used in this study.
For the samples subjected to RNA-Seq, we isolated 5
μg of total RNA from each sample and prepared them
for high-throughput sequencing following the standard
mRNA protocol by Illumina, unless specified otherwise.
Briefly, mRNA from each sample was purified using
Sera-mag magnetic oligo(dT) beads (Thermo Scientific)
[for SUM149PT, Ribominus beads (Invitrogen) was
applied to deplete ribosomal RNA species], fragmented
at high temperatures into random fragments, and
reverse-transcribed into cDNA using Superscript II
(Invitrogen).
Illumina Genome Analyzer sequencing
Each prepared cDNA library was subjected to high-
throughput sequencing using the Illumina Genome Ana-
lyzer IIx platform, following the standard RNA sequen-
cing protocol. Samples were sequenced at various sites
and times and are described as follows: HCC1937 was
sequenced by Illumina (50 bp SE). SUM149PT, SEC1
and SEC2 were sequenced at the Institute of Cancer
Research (36 bp, 54 bp and 54 bp PE, respectively).
SUM1315O2, HCC3153, HCC2337, T92, T50, T160 and
MCF10A were sequenced at the McGill University and
Genome Quebec Innovation Centre (76 bp PE per sam-
ple). All reads were processed using ELAND (AJ Cox,
unpublished) to generate FASTQ files. Due to poor base
quality at the 3’ end of SUM1315O2 and HCC3153,
reads in these samples were trimmed by 40 bp from the
3’ end to produce 36 bp high quality PE reads. Addi-
tional read statistics are summarized in Additional file 1.
RNA-Seq post-processing
Illumina FASTQ reads were first converted to Sanger
FASTQ format using the ill2sanger script (patch by D
Cittaro) from MAQ (http://maq.sourceforge.net/). Reads
were then aligned to the human reference genome
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Page 2 of 13(hg18) using BWA [25]. Reads that span an exon-exon
splice junction will not map to the reference since it will
be separated by an intron. Thus, the remainder of the
unmapped reads were aligned to a custom library of
junction sequences based on known RefSeq annotation.
For each splice junction and read length x, we joined x-
5b p( o rt h el e n g t ho ft h ee x o ni fl e s st h a nx-5) of
sequence from the upstream exon with x-5 bp (or the
length of the exon if less than x-5) of the downstream
exon. This ensured that reads mapping to a splice junc-
tion overlapped to at least 5 bp of either end of the
junction. The results were then processed using SAM-
Tools [26] for downstream analysis. Visualization of the
mapped reads was carried out using Integrated Genome
Viewer (http://www.broadinstitute.org/igv).
Identification of gene fusion transcripts from RNA-Seq
In this study, we implemented two strategies adapted
from methods described by Maher et al. [3,4] to facili-
tate gene fusion discovery with SE reads and PE reads,
respectively.
I nt h eS Ea p p r o a c h ,g e n ef u s i o n sa r ei d e n t i f i e db y
checking for reads which map across the exon-exon
fusion junction between the two fused genes. To sim-
plify the analysis, we reasoned that only the subset of
reads which did not fully align to the reference genome
or splice junctions would be interesting (unmapped
reads), as they may harbour fusion junction spanning
reads. All unmapped reads were realigned to RefSeq
mRNA sequences using Blat [27]. Reads that partially
aligned to a RefSeq sequence (20-70% identity) and did
not fully map to anything else were retained. Ambiguous
reads that were partially aligned to more than five genes
were also discarded. Based on the position of the align-
ment, we further filtered for reads that partially aligned
w i t h i n5b po fa ne x o nb o u n d a r yu s i n gR e f S e qa n n o t a -
tion. This is because we expected that potential reads
mapping across a gene fusion junction would be align-
ing at the exon boundaries. The resulting set of partially
aligning reads was denoted as group A. Next, the una-
ligned portions of these reads were extracted and again
subjected to alignment against RefSeq mRNA exon
sequences using Vmatch [28], for effective alignment of
shorter reads (<20 bp). Reads that fully mapped to an
exon and localized within 5 bp of 5’ end or 3’ were
retained in a similar fashion as before (denote as group
B). Finally, we combined the results from group A with
group B by finding reads that had a partial alignment in
group A and a full alignment in group B, thus account-
ing for the entire read sequence and ultimately repre-
senting a gene fusion candidate read (GFCR). All the
GFCRs were tallied and summarized. Fusion partners
with greater than or equal to three unique GFCRs were
considered a gene fusion candidate. Each candidate was
manually examined to determine its potential biological
significance and to check whether it could be a false
positive. This included disqualifying reads that mapped
to too many loci, which may represent a repetitive
region, or gene fusion candidates which mapped to two
homologs that were part of the same gene family.
For the PE approach, we searched for two features
which may define a gene fusion. First, we limited our
selection to reads that fully and uniquely mapped to the
reference genome. Second, we reasoned that reads
which map to different chromosomes may reflect an
interchromosomal translocation and have the potential
to form a gene fusion. Alternatively, reads that map to
the same chromosome but at a larger than expected dis-
tance apart may represent an intrachromosomal translo-
cation. However, this may be confounded by large
Table 1 Summary of RNA-Seq samples
Sample name Sample description BRCA1 mutation Sequencing strategy
HCC1937 Cell line 5266dupC SE
SUM149PT Cell line 2769delT PE
SUM1315O2 Cell line 30_31delAG PE
HCC3153 Cell line 815_824dup PE
T92 Primary tumor 5266dupC PE
T50 Primary tumor 4327C>T PE
T160 Primary tumor 5521A>C* PE
HCC2337 Lymphocyte cell line 5266dupC PE
MCF10A Non-tumorigenic breast epithelial cell line - PE
SEC1 Primary tumor - PE
SEC2 Primary tumor - PE
* See Lee et al. [58] for more details
Ten breast cancer samples (eight with known germline BRCA1 mutations and two secretory breast cancers) and one non-tumorigenic breast epithelial control
was sequenced using the Illumina Genome Analyzer IIx. Only HCC1937 was sequenced using a single-end (SE) strategy, while the rest was sequenced using
paired-end (PE). The cell line HCC2337 is a lymphocytic cell line derived from the same patient as HCC1937. Known BRCA1 mutations are based on RefSeq
accession NM_008294.3.
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Page 3 of 13introns situated between two exons that the reads map
to. To account for this, we used an arbitrary minimum
intrachomosomal mapping distance of 1 Mb. After iden-
tifying such read pairs, we realigned the reads to RefSeq
mRNA sequences using Blat. Ensuring that each read in
a pair mapped to a different gene, we summarized a list
of candidate gene fusions in a similar fashion as for SE
reads and generated a paired end fusion score (PEFS).
The scoring scheme was defined as follows: +2 for each
identified read pair, -1 for each duplicate read, and -0.5
for each mismatch in a read. We prioritized those that
had a minimum of three read pairs that flanked a fusion
junction and had a minimum PEFS score of 5. For
further supporting evidence of each finding, we searched
for additional reads that spanned across the fusion junc-
tion, analogous to the SE approach but restricted to a
search space containing only the two partner genes.
Here, we generated a library of all possible splice junc-
tion sequences between the 5’ fusion partner and the 3’
fusion partner, which includes the predicted fusion junc-
tion. All remaining unmapped reads were aligned to
these junction sequences using Blat.
Quantification of exon expression levels
Exon expression levels were quantified by first determin-
ing the number of reads that uniquely mapped to each
exonic region using BEDTools [29]. The genomic coor-
dinates for each exon were obtained from the UCSC
Table Browser [30]. The number of reads was normal-
ized and expressed as reads per kilobase of exon model
per million mapped reads (RPKM) [31].
Sanger sequencing
Primer pairs for PCR amplification and sequencing of
each coding exon were generated using Primer3 [32].
Primers (see Additional file 2 for sequences) were
designed to span the predicted exons forming the fusion
breakpoint and to generateam a x i m u mp r o d u c ts i z eo f
300 bp, which was considered optimal for amplification,
purification, and sequencing. To minimize amplification
of homologous genomic sequences, primer pairs were
filtered using the UCSC In Silico PCR software, and
only pairs yielding a single product were used. PCR
reactions were performed on the cell lines’ cDNA at
least twice, using the following thermocycling para-
meters: 95°C × 15 min, (95°C × 20 s, 60°C × 20 s, 72°C
× 20 s) for 30 cycles, 72°C × 10 min. PCR products
were purified as recommended by the manufacturer
(QIAGEN). Products were sequenced by conventional
Sanger methods and compared to the reference
sequence to validate the gene fusion. Sequence products
were obtained from MUGQIC. Sequence chromato-
grams were aligned and analyzed with the Staden pack-
age and Mutation surveyor software version 3.24.
RT-PCR
Total RNA (100 ng) was reverse transcribed into single-
stranded cDNAs using SuperScript III reverse transcrip-
tase (Invitrogen) and Oligo (dT)12-18 (Invitrogen) in 20
μl reaction at 50°C for 50 min, 85°C for 5 min, 37°C for
20 min. 2 μl of cDNA was used for a subsequent 20 μl
PCR amplification. To detect fusion transcripts, we
design the forward primer targeting the 5’ partner gene
and reverse primer targeting the 3’ partner. Primer pairs
(see Additional file 2 for sequences) for the coding
exons of the fusion genes were generated using Primer3
[32]. GAPDH was amplified simultaneously. PCR was
performed at an annealing temperature of 60°C for 26
cycles. PCR products were separated by gel electrophor-
esis in a 3% agarose gel (Metaphor, MRC) and visualized
by ethidium bromide staining.
Data access
Sequence data of the breast cancer cell lines (HCC1937,
SUM149PT, SUM1315O2, HCC3153, HCC2337 and
MCF10A) from this study has been deposited to the
NCBI Sequence Read Archive (http://trace.ncbi.nlm.nih.
gov/Traces/sra/sra.cgi) under accession no. SRA046769.
Results
Application of RNA-Seq to identify gene fusion transcripts
Initially in this study, we relied on using SE reads to
identify gene fusions in the HCC1937 cell line. The
remainder of this study was subsequently superseded by
the PE approach, which relies on identifying read pairs
that fully map to two different genes. To prioritize can-
didates for further review, we implemented a scoring
scheme that assigned a paired end fusion score (PEFS)
based on various characteristics of the read mapping.
For example, a candidate with three mapped read pairs
was awarded 2 points for each pair and thus had total
PEFS of 6. However, a penalty of -1 was given for each
read that had the same start coordinate as another sup-
porting read. Such reads imply that they are duplicate
reads and, although it is difficult to distinguish, may
represent PCR duplicates originating from the amplifica-
tion step during sequencing [33]. Hence, preference was
given to candidate fusions that were supported by
unique reads. Furthermore, by incorporating additional
reads spanning the predicted fusion junction, the PE
approach provides two unique pieces of evidence to sup-
port the discovery of gene fusion transcripts.
Proof of concept
To evaluate our implementation, we attempted to iden-
tify known gene fusions within our samples. We applied
our SE approach on HCC1937. This cell line has been
previously found to have a translocation involving exon
2o fNFIA on chromosome 1 joining with exon 5 of
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Page 4 of 13EHF on chromosome 11 using massively parallel DNA
sequencing [24]. We were able to successfully confirm
the expression of NFIA-EHF in the transcriptome of this
cell line. Several 50 bp reads were mapped across the
junction between exon 2 of NFIA and exon 5 of EHF
(Figure 1A).
Next, we tested the PE approach on two primary
tumors (SEC1 and SEC2) with secretory breast ductal
carcinoma, a rare subtype of breast cancer. These sam-
ples were tested by other molecular methods to harbour
the gene fusion ETV6-NTRK3 [34]. This fusion is caused
by a balanced translocation, t(12;15)(p13;q25), joining
exon 5 of ETV6 and exon 14 of NTRK3 and is recurrent
in this cancer [18]. Furthermore, functional studies have
established the fusion to have a causative role in the
pathogenesis of this breast cancer subtype [35,36]. We
successfully confirmed the gene fusion transcript in
SEC2 by identifying read pairs that flanked the fusion
junction as well as individual reads mapping across the
fusion junction (Figure 1B). The reciprocal fusion, invol-
ving exon 13 of NTRK3 as the 5’ partner gene and exon
6o fETV6 as the 3’ gene, was also identified in the
same sample. On the other hand, we could not find the
fusion in SEC1. Since no supporting PE reads were
found, we checked to see if there were only individual
reads that mapped across the ETV6-NTRK3 fusion junc-
tion. To test this, we mapped our reads to a custom-
generated ETV6-NTRK3 junction sequence using Blat
Figure 1 RNA-Seq evidence of previously described gene fusions. We first tested our SE approach on (A) the HCC1937 cell line that
harbours the fusion NFIA-EHF. SE reads are shown to map across the exon-exon fusion junction between exon 2 of NFIA and exon 5 of EHF,a s
illustrated in the schematic. Next, we tested our PE approach on (B) two primary tumors that contain ETV6-NTRK3. Results from the sample SEC2
are shown. Paired reads (indicated by two solid lines joined by a dotted line) as well as single reads (red lines) are shown to map across the
fusion junction between exon 5 of ETV6 and exon 14 of NTRK3.
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Page 5 of 13[27] and did not find any supporting reads. Subsequent
inspection of starting sample from which SEC1 was pre-
pared indicated that the tumor content was less than
50%. Hence, there may have been insufficient content of
this gene fusion to be detected by RNA-Seq.
Discovery of gene fusions
We analyzed the remaining samples for novel gene
fusions. From the initial list of candidates, we found that
many of the candidates with fewer than three supporting
paired reads were due to duplicated reads, which may
represent false positives. Samples T50 and T160, in par-
ticular, were sequenced at a higher depth than the other
samples, yielding more sequencing data. A summary of
the number of fusions found in each sample is shown in
Table 2 In total, we found four candidates in samples
with BRCA1 mutations that were supported by both
misaligning PE reads and individual fusion junction-
spanning reads. No fusions were identified in MCF10A.
We manually inspected each of the four candidates and
found that three of them formed in-frame transcripts, as
described below and summarized in Table 3.
We identified a novel in-frame interchromosomal
fusion transcript in SUM149PT involving exon 6 of
MTAP on chromosome 9 joining with exon 3 of PCDH7
on chromosome 4. We found five read pairs flanking the
fusion junction and two individual reads spanning the
junction (Additional file 3A). The 5’ gene, MTAP,
encodes for a methylthioadenosine phosphorylase that
has been frequently observed to be co-deleted with
tumor suppressor gene encoding p16 in numerous can-
cers [37]. Interestingly, a deletion resulting in a fusion
protein between MTAP and tumor suppressor gene
encoding p15
INK5B was reported in a glioma xenograft as
well as other malignant cell lines [38]. The 3’ gene,
PCHD7, encodes for an extracellular protocadherin
protein involved in cell-cell recognition and adhesion.
We were unable to amplify the MTAP-PCDH7 fusion
junction using RT-PCR of cDNA in SUM149PT. One
possible explanation for this failure could be due the low
expression of both genes in this sample. We investigated
this by examining their gene expression profiles in the
RNA-Seq data, as will be discussed later.
A second in-frame interchromosomal fusion transcript
was found in HCC3153 involving exon 19 of WWC1 on
chromosome 5 joining with exon 10 of ADRBK2 on
chromosome 22. We found three read pairs flanking the
fusion junction and seven individual reads spanning the
junction (Figure 2A). The 5’ gene, WWC1, encodes for a
protein KIBRA, a cytoplasmic phosphoprotein that regu-
lates the Hippo/SWH signaling pathway and has been
shown to be involved in tumor suppression [39]. The 3’
gene, ADRBK2, encodes for a beta-adrenergic receptor
kinase involved in the phosphorylation of G protein-
coupled receptors. The ATP binding and kinase
domains of this gene are conserved in the predicted
fusion. To verify our finding, we performed PCR ampli-
fication of the WWC1-ADRBK2 cDNA at the fusion
junction followed by Sanger sequencing (Figure 2B).
Furthermore, in a separate experiment not described in
this study, HCC3153 was subsequently re-sequenced at
the Institute of Cancer Research using RNA-Seq on the
Illumina Genome Analyzer. Our analysis of this data re-
confirmed the expression of the predicted fusion tran-
script (data not shown). To determine for recurrence,
we additionally screened a cDNA panel of 57 breast
cancers and did not find the fusion in any of the cases.
A third in-frame intrachromosomal fusion transcript
was identified in a primary tumor T50 involving exon 2
of ADNP and exon 17 of C20orf132, both of which are
located on chromosome 20 (Figure 3A). Interestingly,
while identifying additional reads that mapped across
the fusion junction, we found read evidence supporting
an additional fusion isoform of ADNP-C20orf132 invol-
ving exon 1 of ADNP instead of exon 2 (Figure 3C).
However, no PE reads were found to be discordantly
mapped across this fusion isoform. Notably, exon 2 is
Table 3 Candidate gene fusions supported by PE and
junction spanning reads with PEFS >= 5
Sample 5’ partner 3’ partner PEFS In-frame? Reference
HCC1937 NFIA EHF N/A Y [24]
SEC2 ETV6 NTRK3 5.0 Y [18,34]
SUM149PT MTAP PCDH7 9.5 Y -
HCC3153 WWC1 ADRBK2 5.0 Y -
T50 ADNP C20orf132 10.0 Y -
T160 CCDC126 HSP90AA1 9.5 N -
In addition to confirming two previously described gene fusions, we identified
four novel gene fusions candidates that were selected based on our filtering
criteria. Among these, three of the candidates were in-frame.
Table 2 Summary of candidate gene fusions identified by
paired end RNA-Seq
Sample PEFS
>0
PEFS >=
5
PEFS >= 5 plus junction spanning
reads
SUM149PT 1 1 1
SUM1315O2 20 2 0
HCC3153 8 1 1
T92 13 0 0
T50 1090 2 1
T160 437 4 1
HCC2337 14 2 0
MCF10A 10 0 0
In order to prioritize gene fusion candidates with the most read support, we
selected candidates with a minimum PEFS of 5 for further investigation. A
total of 12 gene fusion candidates with a PEFS >= 5 were identified based on
discordantly aligned paired reads. Of these, four candidates (33%) were
further found to have supporting reads spanning the exon-exon fusion
junction.
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a long and short wild-type transcript isoforms. Both of
these two exons are located in the 5’ UTR of ADNP,
suggesting that this gene fusion may encode for a trun-
cated version of C20orf132. ADNP encodes for an activ-
ity-independent neuroprotector homeobox protein that
has been found to be involved in cell survival, due to its
proximity to a region that is frequently amplified in can-
cer, 20q12-13.2 [40]. On the other hand, C20orf132 is an
uncharacterized protein and no functional annotation
was available. We validated both fusion transcript iso-
forms using Sanger sequencing (Figure 3B and 3D) and
RT-PCR (Additional file 4) of cDNA from the primary
tumor. Furthermore, we were not able to find evidence
of this gene fusion expressed in the panel of 57 breast
cancer samples discussed above, suggesting that it is not
recurrent.
Lastly, by sequencing HCC1937 and HCC2337, a
tumor cell line and matched lymphocyte cell line
derived from the same patient, respectively, we sought
to determine whether NFIA-EHF was a germline muta-
tion or an acquired somatic mutation. Our analysis
could not detect the expression of this gene fusion in
HCC2337, suggesting that it represents the latter. As an
additional observation, we confirmed via visual inspec-
tion of the mapped reads the presence of three muta-
tions originally reported by Tomlinson et al. [41]: 1) a
5266dupC germline mutation in BRCA1; 2) a somatic
deletion of PTEN; and 3) a somatic C->T substitution in
TP53 (data not shown).
Expression profiling of candidate gene fusions
We next studied the expression profiles of the candidate
gene fusions based on our RNA-Seq data (Methods).
Figure 2 RNA-Seq and Sanger sequencing of WWC1-ADRBK2. We identified an in-frame gene fusion transcript in HCC1315: (A) schematic of
the predicted gene fusion illustrating RNA-Seq evidence that support the fusion between exon 19 of WWC1 and exon 10 of ADRBK2. Reads are
indicated by black solid lines. Paired reads are indicated by the dotted line joining two reads. Reads that span across the fusion junction are
highlighted by red solid lines; and (B) the fusion junction was verified using Sanger sequencing of cDNA.
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quantified using a normalized metric described by Mor-
tazavi et al. [31] called reads per kilobase of exon model
per million mapped reads (RPKM). For each exon e,w e
examined the expression fold change (FC) ratio between
the sample that the fusion gene is present in (denote as
eS) and the average of our other fusion-negative samples
(denote as eR). Formally, we define FC = RPKM(eS)/
RPKM(eR).
Our analysis of MTAP-PCHD7 showed that both
genes were not highly expressed in SUM149PT
compared to the other samples. This was illustrated by
plotting the log2-transformed FCs of all exons in each
gene, as shown in Additional file 3B. Interestingly, for
WWC1-ADRBK2,w eo b s e r v e dad i s c o r d a n c ei ne x p r e s -
sion delineated at the predicted fusion breakpoint of
both partner genes (Figure 4A-B). Furthermore, the
retained 3’ part of ADRBK2 showed increased expres-
sion over the other samples, which may be indicative of
transcriptional activationd r i v e nb yaf o r e i g np r o m o t e r
or enhancer in WWC1. To experimentally confirm that
t h ew i l d - t y p et r a n s c r i p t so ft h e s et w og e n e sw e r en o t
Figure 3 RNA-Seq and Sanger sequencing of ADNP-C20orf132. We identified another in-frame gene fusion in a primary tumor that was
present as two transcript isoforms: (A) schematic of the first predicted gene fusion isoform illustrating RNA-Seq evidence that support the fusion
between exon 2 of ADNP and exon 17 of C20orf132; (B) Sanger sequencing of the fusion junction of the first isoform; (C) while searching for
fusion junction-spanning reads, we subsequently identified a second isoform in which exon 1 of ADNP was fused with exon 17 of C20orf132; and
(D) Sanger sequencing of the fusion junction of the second isoform. Reads are indicated by black solid lines. Paired reads are indicated by the
dotted line joining two reads. Reads that span across the fusion junction are highlighted by red solid lines.
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Page 8 of 13Figure 4 Expression profile of WWC1 and ADRBK2. We studied the gene expression profiles of WWC1 and ADRBK2: (A) Expression plot of
WWC1 exons as measured by the log2 fold change (FC) between the RPKM values of each exon in HCC3153 versus the average of all other
WWC1-ADRBK2-negative samples. The predicted gene fusion junction is marked by an arrow. It can be seen that exons downstream of exon 19
in WWC1 is underrepresented in HCC3153. (B) Similarly, the same can be observed in the exons upstream of exon 10 in ADRBK2. Moreover, the
3’ end of the gene appears to be overexpressed. (C) Two sets of primers were designed to test for expression. The first set, F1 and R1, spanned
exons 9 and 10 of ADRBK2 to test for wild-type expression. Similarly, the second set, F2 and R2, spanned exons 19 and 20 of WWC1. Both sets
were also combined to test for expression of predicted WWC1-ADRBK2 fusion. The expected fragment sizes are shown in brackets. (D) Exon-exon
RT-PCR results: a normal control was tested for the wild-type expression of ADRBK2 by F1/R1 (lane 1), the wild-type expression of WWC1 by F2/R2
(2), and with both sets together (3). In lane 4, both primer sets were applied on HCC3153 and confirmed expression of the expected fusion
fragment but no wild-type expression.
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Page 9 of 13expressed, we designed primers using RT-PCR (Figure
4C). As expected, only the fusion fragment was detected
in HCC3153 (Figure 4D). Lastly, we repeated the exon
expression analysis for ADNP-C20orf132 and similarly
found discordant expression in C20orf132.H e r e ,t h e
exons at the 3’ end of the C20orf132 (exons 17-24) were
expressed higher than the 5’ end (exons 1-16) (Addi-
tional file 4).
Overlap with known copy number variation and
chromosomal breakpoints
Gene fusions have been shown to be linked with geno-
mic imbalances caused by copy number variation (CNV)
[42]. While we do not have the necessary genomic data
to interrogate CNVs within our samples for this study,
we nonetheless explored whether the genes identified
above overlapped with any known structural variation in
the Database of Genomic Variants [43] and previously
published array comparative genomic hybridization
(aCGH) data on breast cancer cell lines [44]. In the for-
mer, at least one CNV was identified for all six genes
examined (Additional file 5A-i and 5B). Among these,
ADRBK2 had the most reported CNVs (n = 12) overlap-
ping the 5’ end of the gene. The majority of these
CNVs, although rare, were centred approximately 300-
500 kb upstream of ADRBK2 in a region that was
enriched with segmental duplications. In the latter, the
authors performed aCGH using 1 Mb resolution arrays
to study CNVs in breast cancer cell lines including
SUM149PT and HCC3153. To determine whether there
were copy number changes near our genes, we exam-
ined the log2 fold changes of BAC clone(s) whose start
position was within 1 Mb upstream and downstream of
our genes (Additional file 5A-ii). For both MTAP and
PCDH7 in SUM149PT, copy number losses were
reported in BAC clones nearest these genes. In
HCC3153, no BAC clones near ADRBK2 was found
while copy number loss was reported near WWC1.
However, more studies will be required to elucidate the
relationship between these genes, their predicted rear-
rangement, and copy number within our specific cohort.
Finally, to gain insight on the frequency of chromosomal
breakpoints occurring near these genes, we consulted
the Mitelman Database of Chromosome Aberrations
and Gene Fusions in Cancer [45] to find previously
reported breakpoints occurring near these genes (Addi-
tional file 5A-iii). The chromosomal region encompass-
ing ADRBK2 was found to have the most number of
cases with a reported breakpoint (n = 5193).
Discussion
We have leveraged the power of massively parallel RNA
sequencing to interrogate the transcriptomes of BRCA1-
mutated breast cancer cell lines and tumors for putative
gene fusions. In addition to identifying previously
described gene fusions, we identified three novel in-
frame fusions, MTAP-PCDH7 in SUM149PT, WWC1-
ADRBK2 in HCC3153 and ADNP-C20orf132 in one pri-
mary tumor. Only the latter two were confirmed by RT-
PCR and Sanger sequencing.
Gene fusions can adversely affect an organism by
deregulating the normal expression and disrupting the
function of genes. There are two main ways in which
this occurs [46]. First, the active domain of one gene is
joined with a regulatory enhancer or promoter of
another gene, causing an upregulation of the active
domain and leading to oncogenesis. Second, a hybrid or
chimeric gene fusion is formed such that characteristics
from both genes are active. Interestingly, for both
WWC1-ADRBK2 and ADNP-C20orf132,w eo b s e r v e d
discordant expression delineated at the predicted break-
point region of each gene. In both cases, expression was
markedly higher in the 3’ partner gene compared to
samples that were negative for the gene fusion of inter-
est. Hence, this suggests that they may represent exam-
ples of the first mechanism. Gene fusions are also
known to be associated with CNVs [42]. While we
observed some previously reported CNVs near the
selected fusion genes, no conclusions could be drawn on
their functional relationship.
None of the predicted gene fusions were found to be
recurrent in any of the other samples that were
sequenced. This raises the question of whether these
fusions represent driver mutations that directly contri-
bute to tumorigenesis or are passenger effects that have
minor or no consequence. It is well understood that dri-
ver gene fusions are typically found to be recurrent,
such as BCR-ABL, ETV6-NTRK3,a n dTMPRSS2-ERG in
prostate cancer [47], and consequently they are ideal
targets for therapeutic intervention. Since we were
unable to detect any of our novel fusions in our screen-
ing of additional BRCA1-mutated, BRCA2-mutated or
BRCA1/2-unrelated breast cancers, they may represent
non-recurrent passenger mutations. However, more
experimental studies will be required to elucidate their
functional role. Moreover, many fusions that have been
reported in literature have been found to be rare and
have a low recurrence rate [48]. Hence, such low fre-
quency gene fusions that are found in cancer may still
be worth noting. If they can be observed in a patient,
such private mutations can be potentially used as part
of a personalized treatment program. For example,
Leary et al. [49] recently demonstrated the ability to
identify patient-specific genomic rearrangements as bio-
markers in solid tumors using massively parallel sequen-
cing. Indeed, our identification of ADNP-C20orf132 in a
primary tumor represents one example of a private bio-
marker which may be used to track the status of the
Ha et al. BMC Medical Genomics 2011, 4:75
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Page 10 of 13patient. Therefore, the use of sequencing-based
approaches will be vital for advancing our understanding
of tumors and to catalogue all known genetic abnormal-
ities [50].
For this study, we focused our analysis on a collection
of breast cancer samples with BRCA1 mutations. Tumors
of this type may possess a distinctive, possibly unique,
expression signature, despite their resemblance to basal-
like and triple-negative breast cancers [51,52]. Hence,
there has been great interest in elucidating the molecular
mechanisms in BRCA1 cancers to identify potential bio-
markers and drug targets. For example, genes that are
more relied upon by tumor cells as a result of the loss of
BRCA1 function can be targeted for inhibition and result
in cell death. This synthetic lethal relationship has led to
findings of potential drug targets that are sensitive to
inhibition in BRCA1 tumors, such as mitogen-activated
protein kinase [53] and poly (ADP-ribose) polymerase
(PARP) [54]. In the case of the latter, a PARP inhibitor,
olaparib (AstraZeneca) has already been developed and
undergone successful clinical trials [54]. Knowledge of
t h er o l eo fg e n ef u s i o n si nBRCA1 breast cancers, how-
ever, is limited. In a study by Stephens et al. [24], gene
fusions were identified in breast cancer genomes, but
none of them were recurrent. We hypothesized that
mutations in BRCA1 may increase the frequency of chro-
mosomal aberrations due to defects in the DNA repair
and NHEJ pathways. This in turn, could result in the
expression of novel gene fusions that can be observed at
the transcriptome level. As discussed above, our analysis
of a limited number of samples did not reveal strong evi-
dence of gene fusions as major contributors to the devel-
opment of BRCA1 breast cancers. However, this does not
discount other genomic instabilities and lesions that arise
from BRCA1 mutations and are not detected by RNA-
Seq. For example, studies have shown that BRCA1 has a
role in centrosome function and the organization of
chromosomes [55,56]. We expect future studies to
involve analyzing a greater number of samples by mas-
sively parallel sequencing at the genomic and transcrip-
t o m i cl e v e l ,a l l o w i n gf o ram o r ep o w e r f u la n d
comprehensive interrogation of breast cancer.
We demonstrate the merits of using RNA-Seq to dis-
cover gene fusions. In particular, we note that our
method to examine discordant expression between
exons is related to a previously described approach to
predict gene fusions using exon arrays [57]. However,
while candidate fusion genes can be identified based on
discordant exon expression, it can be difficult to deter-
mine which pair of genes is involved in the fusion. A
sequencing-based approach can overcome this by addi-
tionally identifying reads that map across the exon-exon
fusion junction. Initially, we explored using a strategy
based on SE reads. Maher et al. [3] previously described
an approach that leveraged both longer reads (> 250 bp)
followed by short reads (35 bp) to find gene fusions.
Since while initially working with HCC1937 we only had
short 50 bp SE reads, a major challenge was to identify
reads that partially aligned to two different genes. For
example, a typical partial alignment may involve finding
matching sequences less than 50% the length of the
read (in this case, < 25 bp) that map to a gene. Given
the large number of genes to be searched, it is likely
that many of the shorter sequences will be matched in a
non-specific manner. We mitigated this by filtering for
matches that occur at or near the boundary of exons.
Another approach was through the use of PE reads,
which alleviated the reliance on finding junction span-
ning reads in the initial step [4]. Instead, we first sys-
tematically searched for paired reads that fully mapped
to the genome but not at the expected distance or
orientation, followed by searching for individual reads
mapping across the predicted fusion junction. We also
note two caveats to our approach. First, we identified
candidate gene fusions based on RefSeq annotation for
well-characterized content. As a result, some non-
RefSeq genes may have been missed. Second, lowly
expressed gene fusion transcripts are generally more dif-
ficult to detect if there is insufficient read coverage at
the junction site and do not have supporting discordant
PE reads. Thus, we focused on gene fusion candidates
with adequate read coverage for further validation. In
general, we found that the paired read property of PE
reads allowed us to identify candidates with greater
effectiveness than using only SE reads.
Conclusions
The emergence of massively parallel RNA sequencing
has enabled the direct profiling of transcriptomes and
revolutionized transcriptomics research. With this tech-
nology, we found that the use PE reads is well-suited for
the discovery of gene fusions in cancer via bioinfor-
matics approaches. Our investigation of several BRCA1-
mutated breast cancer cell lines and primary tumors
revealed three previously uncharacterized non-recurrent
gene fusions, two in cell lines and one in a primary
tumor. While their functional role remains to be deter-
mined, no strong evidence was found to suggest that
they are predominant in these cancers. However, their
identification may serve as viable patient-specific bio-
markers. Thus, the discovery and cataloguing of gene
fusions will play an important role in the clinical treat-
ment of solid tumours.
Additional material
Additional file 1: Read statistics of RNA-Seq samples. A summary of
read statistics of the RNA-Seq samples used in this study.
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Page 11 of 13Additional file 2: Primer sequences for experimental validation. This
document contains the primer sequences used for experimental
validation of candidate gene fusions (Sanger sequencing and RT-PCR).
Additional file 3: Schematic and expression profile of MTAP-PCDH7
gene fusion. (A) Schematic illustrating paired-end reads that flank the
fusion junction between exon 6 of MTAP and exon 3 of PCDH7. Reads
are indicated by black solid lines. Paired reads are indicated by the
dotted line joining two reads. Reads the span across the junction are
highlighted by red solid lines; and (B) Expression plots of MTAP and
PCDH7 as measured by the log2 FC between the RPKM values of each
exon in SUM149PT versus the average of all other MTAP-PCDH7-negative
samples.
Additional file 4: Expression profile of ADNP-C20orf132 gene fusion.
We extracted cDNA from primary tumor T50 and confirmed the presence
of both isoforms of ADNP-C20orf132 by (A) RT-PCR. In both cases, we
confirmed the presence of both isoforms (lanes 1 and 2) of this gene
fusion. Lane 3 is a 50 bp ladder control. (B) Expression plots of ADNP and
C20orf132 as measured by the log2 FC between the RPKM values of each
exon in the T50 versus the average of all other ADNP-C20orf132-negative
samples.
Additional file 5: Genomic features overlapping or near candidate
fusion genes. (A) We queried existing data to summarize known
structural variation that overlaps or is within proximity of our candidate
fusion genes; and (B) a list of overlapping CNVs reported in the Database
of Genomic Variants.
Acknowledgements
This work was supported by funding from the United States Department of
Defence (grant no. W81XWH-08-1-0402), Susan G. Komen for the Cure,
Montreal Jewish Hospital Weekend to End Women’s Cancer, Canadian
Institutes of Health Research and Genome Canada/Génome Québec. JM is a
Canada Research Chair recipient. WDF is supported by the Turner Family
Cancer Research Fund and holds a Fonds de la Recherche en Santé du
Québec (FRSQ) national scientist award. We would like to thank Archana
Srivastava and the Génome Québec Sequencing Platform team for their
assistance.
Author details
1Department of Human Genetics, McGill University, Room N5-13, Stewart
Biology Building, 1205 Dr. Penfield Ave, Montreal, Quebec, H3A 1B1, Canada.
2McGill University and Genome Quebec Innovation Centre, 740 Dr. Penfield
Ave, Montreal, Quebec, H3A 1A4, Canada.
3Program in Cancer Genetics,
McGill University, 546 Pine Ave, Montreal, Quebec, H2W 1S6, Canada.
4Segal
Cancer Centre, Lady Davis Institute, Jewish General Hospital, 3755 Côte-Ste-
Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
5The Breakthrough
Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham
Road, London, SW3 6JB, UK.
6Institut Curie, 26 Rue d’Ulm, 75248, Paris,
France.
7Department of Oncology, Lady Davis Institute, Jewish General
Hospital, McGill University, 3755 Côte-Ste-Catherine Road, Montreal, H3T 1E2,
Canada.
8Department of Surgery, Lady Davis Institute, Jewish General
Hospital, McGill University, 3755 Côte-Ste-Catherine Road, Montreal, Quebec,
H3T 1E2, Canada.
Authors’ contributions
KCHH implemented and performed the computational analysis for gene
fusion discovery in RNA-Seq data. EL performed the initial alignment of
reads to the reference genome and splice junctions library. CM, JH, CJL and
AA contributed to early versions of sequence alignment pipelines. LL, LC
and MBL designed and carried out experimental validation of the candidate
gene fusions. LC performed further experimental testing on additional
cohorts. RN, KF, IK and CJL carried out the massively parallel RNA
sequencing at the London site. AVS provided the secretory breast carcinoma
samples. MB provided the BRCA1 tumor samples. WDF provided the cell line
samples. WDF also provided additional BRCA1/BRCA2-related and BRCA1
wild-type samples for validation. KCHH wrote the manuscript with
contributions by EL, LC, JM and WDF. JM and WDF are co-principal
investigators of this study. All authors have read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 30 July 2011 Accepted: 27 October 2011
Published: 27 October 2011
References
1. Mitelman F, Johansson B, Mertens F: The impact of translocations and
gene fusions on cancer causation. Nat Rev Cancer 2007, 7:233-245.
2. Shtivelman E, Lifshitz B, Gale RP, Canaani E: Fused transcript of abl and bcr
genes in chronic myelogenous leukaemia. Nature 1985, 315:550-554.
3. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X,
Sam L, Barrette T, Palanisamy N, Chinnaiyan AM: Transcriptome
sequencing to detect gene fusions in cancer. Nature 2009, 458:97-101.
4. Maher CA, Palanisamy N, Brenner JC, Cao X, Kalyana-Sundaram S, Luo S,
Khrebtukova I, Barrette TR, Grasso C, Yu J, et al: Chimeric transcript
discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci
USA 2009, 106:12353-12358.
5. Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J,
Johnson LA, Robinson J, Verhaak RG, Sougnez C, et al: Integrative analysis
of the melanoma transcriptome. Genome Res 2010, 20:413-427.
6. Marioni J, Mason C, Mane S, Stephens M, Gilad Y: RNA-seq: an assessment
of technical reproducibility and comparison with gene expression arrays.
Genome Res 2008, 18:1509-1517.
7. Wang Z, Gerstein M, Snyder M: RNA-Seq: a revolutionary tool for
transcriptomics. Nat Rev Genet 2009, 10:57-63.
8. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC,
Langholz B, Bernstein L, Olsen JH, Lynch CF, et al: Variation of breast
cancer risk among BRCA1/2 carriers. JAMA 2008, 299:194-201.
9. Tai YC, Domchek S, Parmigiani G, Chen S: Breast cancer risk among male
BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007,
99:1811-1814.
10. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL,
Loman N, Olsson H, Johannsson O, Borg A, et al: Average risks of breast
and ovarian cancer associated with BRCA1 or BRCA2 mutations detected
in case Series unselected for family history: a combined analysis of 22
studies. Am J Hum Genet 2003, 72:1117-1130.
11. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR,
Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast
tumours. Nature 2000, 406:747-752.
12. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T,
Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of
breast carcinomas distinguish tumor subclasses with clinical
implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
13. Rakha EA, Reis-Filho JS, Ellis IO: Basal-like breast cancer: a critical review. J
Clin Oncol 2008, 26:2568-2581.
14. Reis-Filho JS, Tutt AN: Triple negative tumours: a critical review.
Histopathology 2008, 52:108-118.
15. Foulkes WD, Smith IE, Reis-Filho JS: Triple-negative breast cancer. N Engl J
Med 2010, 363:1938-1948.
16. Arnes JB, Begin LR, Stefansson I, Brunet JS, Nielsen TO, Foulkes WD,
Akslen LA: Expression of epidermal growth factor receptor in relation to
BRCA1 status, basal-like markers and prognosis in breast cancer. J Clin
Pathol 2009, 62:139-146.
17. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-
Boussard T, Livasy C, Cowan D, Dressler L, et al: Immunohistochemical and
clinical characterization of the basal-like subtype of invasive breast
carcinoma. Clin Cancer Res 2004, 10:5367-5374.
18. Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA,
Becker L, Carneiro F, MacPherson N, Horsman D, et al: Expression of the
ETV6-NTRK3 gene fusion as a primary event in human secretory breast
carcinoma. Cancer Cell 2002, 2:367-376.
19. Moynahan ME, Chiu JW, Koller BH, Jasin M: Brca1 controls homology-
directed DNA repair. Mol Cell 1999, 4:511-518.
20. Bollag RJ, Waldman AS, Liskay RM: Homologous recombination in
mammalian cells. Annu Rev Genet 1989, 23:199-225.
21. Snouwaert JN, Gowen LC, Latour AM, Mohn AR, Xiao A, DiBiase L, Koller BH:
BRCA1 deficient embryonic stem cells display a decreased homologous
Ha et al. BMC Medical Genomics 2011, 4:75
http://www.biomedcentral.com/1755-8794/4/75
Page 12 of 13recombination frequency and an increased frequency of non-
homologous recombination that is corrected by expression of a brca1
transgene. Oncogene 1999, 18:7900-7907.
22. Lieber MR, Ma Y, Pannicke U, Schwarz K: Mechanism and regulation of
human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003,
4:712-720.
23. Mills KD, Ferguson DO, Alt FW: The role of DNA breaks in genomic
instability and tumorigenesis. Immunol Rev 2003, 194:77-95.
24. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT,
Stebbings LA, Leroy C, Edkins S, Mudie LJ, et al: Complex landscapes of
somatic rearrangement in human breast cancer genomes. Nature 2009,
462:1005-1010.
25. Li H, Durbin R: Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 2009, 25:1754-1760.
26. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G,
Abecasis G, Durbin R: The Sequence Alignment/Map format and
SAMtools. Bioinformatics 2009, 25:2078-2079.
27. Kent WJ: BLAT–the BLAST-like alignment tool. Genome Res 2002,
12:656-664.
28. Abouelhoda MI, Kurtz S, Ohlebusch E: Replacing suffix trees with
enhanced suffix arrays. Journal of Discrete Algorithms 2004, 53-86.
29. Quinlan AR, Hall IM: BEDTools: a flexible suite of utilities for comparing
genomic features. Bioinformatics 2010, 26:841-842.
30. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D,
Kent WJ: The UCSC Table Browser data retrieval tool. Nucleic Acids Res
2004, 32:D493-496.
31. Mortazavi A, Williams B, McCue K, Schaeffer L, Wold B: Mapping and
quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008,
5:621-628.
32. Rozen S, Skaletsky H: Primer3 on the WWW for general users and for
biologist programmers. Methods Mol Biol 2000, 132:365-386.
33. Koboldt DC, Ding L, Mardis ER, Wilson RK: Challenges of sequencing
human genomes. Brief Bioinform 2010, 11:484-498.
34. Lae M, Freneaux P, Sastre-Garau X, Chouchane O, Sigal-Zafrani B, Vincent-
Salomon A: Secretory breast carcinomas with ETV6-NTRK3 fusion gene
belong to the basal-like carcinoma spectrum. Mod Pathol 2009,
22:291-298.
35. Li Z, Tognon CE, Godinho FJ, Yasaitis L, Hock H, Herschkowitz JI, Lannon CL,
Cho E, Kim SJ, Bronson RT, et al: ETV6-NTRK3 fusion oncogene initiates
breast cancer from committed mammary progenitors via activation of
AP1 complex. Cancer Cell 2007, 12:542-558.
36. Euhus DM, Timmons CF, Tomlinson GE: ETV6-NTRK3–Trk-ing the primary
event in human secretory breast cancer. Cancer Cell 2002, 2:347-348.
37. Christopher SA, Diegelman P, Porter CW, Kruger WD: Methylthioadenosine
phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts
as a tumor suppressor in a breast cancer cell line. Cancer Res 2002,
62:6639-6644.
38. Schmid M, Sen M, Rosenbach MD, Carrera CJ, Friedman H, Carson DA: A
methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a
new gene on chromosome 9p21 that is frequently deleted in cancer.
Oncogene 2000, 19:5747-5754.
39. Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N: Kibra is a regulator
of the Salvador/Warts/Hippo signaling network. Dev Cell 2010, 18:300-308.
40. Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E,
Bassan M, Wollman Y, Eyre HJ, Mulley JC, et al: Cloning and
characterization of the human activity-dependent neuroprotective
protein. The Journal of biological chemistry 2001, 276:708-714.
41. Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V,
Blum JL, Schneider NR, Shay JW, et al: Characterization of a breast cancer
cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res
1998, 58:3237-3242.
42. Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R,
Cao X, Varambally S, Thomas DG, et al: An integrative approach to reveal
driver gene fusions from paired-end sequencing data in cancer. Nat
Biotechnol 2009, 27:1005-1011.
43. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW,
Lee C: Detection of large-scale variation in the human genome. Nat
Genet 2004, 36:949-951.
44. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N,
Coppe JP, Tong F, et al: A collection of breast cancer cell lines for the
study of functionally distinct cancer subtypes. Cancer Cell 2006,
10:515-527.
45. Mitelman Database of Chromosome Aberrations and Gene Fusions in
Cancer. [http://cgap.nci.nih.gov/Chromosomes/Mitelman].
46. Rabbitts TH: Chromosomal translocations in human cancer. Nature 1994,
372:143-149.
47. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW,
Varambally S, Cao X, Tchinda J, Kuefer R, et al: Recurrent fusion of
TMPRSS2 and ETS transcription factor genes in prostate cancer. Science
2005, 310:644-648.
48. Mitelman F, Mertens F, Johansson B: Prevalence estimates of recurrent
balanced cytogenetic aberrations and gene fusions in unselected
patients with neoplastic disorders. Genes Chromosomes Cancer 2005,
43:350-366.
49. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A,
Lee C, McKernan K, De La Vega FM, et al: Development of personalized
tumor biomarkers using massively parallel sequencing. Sci Transl Med
2010, 2:20ra14.
50. Velculescu VE: Defining the blueprint of the cancer genome.
Carcinogenesis 2008, 29:1087-1091.
51. Chappuis PO, Nethercot V, Foulkes WD: Clinico-pathological characteristics
of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 2000,
18:287-295.
52. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N,
Trudel M, Akslen LA: Germline BRCA1 mutations and a basal epithelial
phenotype in breast cancer. J Natl Cancer Inst 2003, 95:1482-1485.
53. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R,
Bayani N, Wang NJ, Neve RM, Guan Y, et al: Basal subtype and MAPK/ERK
kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine
susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009,
69:565-572.
54. Rehman FL, Lord CJ, Ashworth A: Synthetic lethal approaches to breast
cancer therapy. Nat Rev Clin Oncol 2010, 7:718-724.
55. Pujana MA, Han JD, Starita LM, Stevens KN, Tewari M, Ahn JS, Rennert G,
Moreno V, Kirchhoff T, Gold B, et al: Network modeling links breast cancer
susceptibility and centrosome dysfunction. Nat Genet 2007, 39:1338-1349.
56. Wang RH, Yu H, Deng CX: A requirement for breast-cancer-associated
gene 1 (BRCA1) in the spindle checkpoint. Proc Natl Acad Sci USA 2004,
101:17108-17113.
57. Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, Pandita A, Tang J,
Modrusan Z: Exon array profiling detects EML4-ALK fusion in breast,
colorectal, and non-small cell lung cancers. Mol Cancer Res 2009,
7:1466-1476.
58. Lee MS, Green R, Marsillac SM, Coquelle N, Williams RS, Yeung T, Foo D,
Hau DD, Hui B, Monteiro AN, Glover JN: Comprehensive analysis of
missense variations in the BRCT domain of BRCA1 by structural and
functional assays. Cancer Res 2010, 70:4880-4890.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1755-8794/4/75/prepub
doi:10.1186/1755-8794-4-75
Cite this article as: Ha et al.: Identification of gene fusion transcripts by
transcriptome sequencing in BRCA1-mutated breast cancers and cell
lines. BMC Medical Genomics 2011 4:75.
Ha et al. BMC Medical Genomics 2011, 4:75
http://www.biomedcentral.com/1755-8794/4/75
Page 13 of 13